NCT02365701已完成2 期
Double-blind, Placebo-controlled, Randomized, 4-week, Phase II Clinical Trial for Assessment of Efficacy and Safety of Motilitone in Patients With Functional Dyspepsia
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 45
- 试验地点
- 1
- 主要终点
- Change in maximum tolerated volume by nutrient drink test
研究概览
简要总结
This study is to evaluate efficacy of the investigational drug Motilitone at 90 mg in patients with Functional Dyspepsia as measured by change in maximum tolerated volume and aggregate symptom score on the nutrient drink test.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •(1) Subject fulfilling Rome III criteria for Functional Dyspepsia: They must have one or more of the following:
- •Bothersome postprandial fullness
- •Early satiation
- •Epigastric pain
- •Epigastric burning AND No evidence of structural disease at upper endoscopy within last 3 months that is likely to explain the symptoms These must be fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis.
- •(2) At least a moderate or severe level within the previous 3 months for two of the following eight symptoms: upper abdominal pain, upper abdominal discomfort, postprandial fullness, upper abdominal bloating, early satiation, nausea, vomiting or excessive belching (each symptom rated as 0: None, 1: Mild, 2: Moderate, 3: Severe).
- •(3) Subjects should be able to provide a written informed consent.
排除标准
- •(1) Subject currently on medication for another study or who participated in another clinical trial or study within 4 weeks before the start of this study.
- •(2) Women of childbearing potential who are not using contraception and pregnant or lactating women.
- •(3) Subject who had surgery that may affect gastrointestinal motility.
- •(4) Subject with known history of gastric bleeding, intestinal obstruction or perforation.
- •(5) Subject with known history of celiac disease, inflammatory bowel disease (Crohn's disease, ulcerative colitis) or microscopic colitis.
- •(6) Subject who had any of the diseases such as reflux esophagitis, gastroduodenal ulcer, gastric adenocarcinoma, esophageal adenocarcinoma, pancreatic disease, etc. that may be an organic cause of dyspepsia.
- •(7) Subject with liver dysfunction (serum glutamic oxaloacetic transaminase/serum glutamic pyruvic transaminase is at least 2.5 times higher than ULN).
- •(8) Subject with renal dysfunction (Serum creatinine level is at least 1.5 times higher than ULN).
- •(9) Subject with a serious cardiovascular (including known baseline QT prolongation defined by >450 msec) or respiratory illness.
- •(10) Subject with diagnosed psychotic illnesses, substance dependence or alcoholism.
- •(11) Subject currently taking drugs that may affect gastrointestinal motility (e.g., anticholinergic, Reglan, erythromycin, azithromycin, Domperidone, etc.), Buspirone, Acotiamide, Tramadol, nonsteroidal anti-inflammatory drug, systemic corticosteroids, and antidepressants, etc. within last 2 weeks of randomization.
- •(12) Medications that can affect QT within last 2 weeks of randomization.
- •(13) Subjects on herbal supplements for Functional Dyspepsia within last 2 weeks of randomization.
- •(14) Subjects with gastric electric stimulator in place.
- •(15) Subjects on narcotics or benzodiazepines within 7 days of randomization.
- •(16) Subjects with score > 12 for anxiety or depression on the Hospital Anxiety and Depression Scale (HADS).
- •(17) Vulnerable study population
研究组 & 干预措施
Motilitone 30mg
Experimental
Motilitone will be administered in tablet form, 3 times daily to subjects randomized to this arm of the study. Subjects will be expected to take this medication for 4 weeks.
干预措施: Motilitone 30mg (Drug)
Placebo
Placebo Comparator
Placebo (same formulation as Motilitone but without the active ingredients) will be administered in tablet form, 3 times daily to subjects randomized to this arm of the study. Subjects will be expected to take this tablet for 4 weeks.
干预措施: Placebo (Drug)
结局指标
主要结局
Change in maximum tolerated volume by nutrient drink test
时间窗: week -2, week 4
Change in aggregate symptom score by nutrient drink test
时间窗: week -2, week 4
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
A Study to Demonstrate the Efficacy and Safety of Motilitone®Functional DyspepsiaNCT01817465Dong-A ST Co., Ltd.389
已完成
2 期
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive DisorderDepressive Disorder, MajorNCT00057213GlaxoSmithKline367
已完成
2 期
An 8 Week Study Of Adults Diagnosed With Major Depressive DisorderDepressive Disorder, MajorNCT00057226GlaxoSmithKline365
已完成
2 期
A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 DepressionDepressive EpisodeBipolar 1 DepressionNCT03543410Sumitomo Pharma America, Inc.344
已完成
3 期
Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental FatSubmental FatNCT05195112Medy-Tox240